Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arata Azuma

Showing results (201-210 of 221) with videos related to

Pageof 23
Sort By:
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
The Journal of Allergy and Clinical Immunology|February 3, 2016
Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populationsYohei Yatagai, Tomomitsu Hirota, Tohru Sakamoto, et al.
The European Respiratory Journal|August 7, 2025
Pulmonary Sarcoidosis Clinical Trial Endpoints: A Delphi StudyRobert P Baughman, Jan C Grutters, Elyse E Lower, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2015
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice GuidelineGanesh Raghu, Bram Rochwerg, Yuan Zhang, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
ERJ Open Research|June 5, 2020
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in JapanYuji Minegishi, Akihiko Gemma, Sakae Homma, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Respiratory Investigation|March 1, 2021
The Japanese respiratory society guidelines for the management of cough and sputum (digest edition)Hiroshi Mukae, Takeshi Kaneko, Yasushi Obase, et al.
Respiratory Research|July 25, 2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)Takekazu Iwata, Ichiro Yoshino, Shigetoshi Yoshida, et al.
Pageof 23

Showing results (201-210 of 221) with videos related to

Sort By:
Pageof 23
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
The Journal of Allergy and Clinical Immunology|February 3, 2016
Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populationsYohei Yatagai, Tomomitsu Hirota, Tohru Sakamoto, et al.
The European Respiratory Journal|August 7, 2025
Pulmonary Sarcoidosis Clinical Trial Endpoints: A Delphi StudyRobert P Baughman, Jan C Grutters, Elyse E Lower, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2015
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice GuidelineGanesh Raghu, Bram Rochwerg, Yuan Zhang, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
ERJ Open Research|June 5, 2020
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in JapanYuji Minegishi, Akihiko Gemma, Sakae Homma, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Respiratory Investigation|March 1, 2021
The Japanese respiratory society guidelines for the management of cough and sputum (digest edition)Hiroshi Mukae, Takeshi Kaneko, Yasushi Obase, et al.
Respiratory Research|July 25, 2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)Takekazu Iwata, Ichiro Yoshino, Shigetoshi Yoshida, et al.
Pageof 23